Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus
- PMID: 25897671
- PMCID: PMC4405357
- DOI: 10.1371/journal.pone.0125109
Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus
Abstract
Serotonin, a highly pro-inflammatory molecule released by activated platelets, is formed by tryptophan. Tryptophan is also needed in the production of kynurenine, a process mediated by the type I interferon (IFN)-regulated rate-limiting enzyme indoleamine 2,3-dioxygenase (IDO). The aim of this study was to investigate levels of serotonin in patients with the autoimmune disease systemic lupus erythematosus (SLE), association to clinical phenotype and possible involvement of IDO in regulation of serotonin synthesis. Serotonin levels were measured in serum and plasma from patients with SLE (n=148) and healthy volunteers (n=79) by liquid chromatography and ELISA, as well as intracellularly in platelets by flow cytometry. We found that SLE patients had decreased serotonin levels in serum (p=0.01) and platelets (p<0.0001) as compared to healthy individuals. SLE patients with ongoing type I IFN activity, as determined by an in-house reporter assay, had decreased serum levels of serotonin (p=0.0008) as well as increased IDO activity (p<0.0001), as determined by the kynurenine/tryptophan ratio measured by liquid chromatography. Furthermore, SLE sera induced IDO expression in WISH cells in a type I IFN-dependent manner (p=0.008). Also platelet activation contributed to reduce overall availability of serotonin levels in platelets and serum (p<0.05). Decreased serum serotonin levels were associated with severe SLE with presence of anti-dsDNA antibodies and nephritis. In all, reduced serum serotonin levels in SLE patients were related to severe disease phenotype, including nephritis, suggesting involvement of important immunopathological processes. Further, our data suggest that type I IFNs, present in SLE sera, are able to up-regulate IDO expression, which may lead to decreased serum serotonin levels.
Conflict of interest statement
Figures
Similar articles
-
Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season.Clin Exp Immunol. 2007 Nov;150(2):274-8. doi: 10.1111/j.1365-2249.2007.03480.x. Epub 2007 Aug 17. Clin Exp Immunol. 2007. PMID: 17711489 Free PMC article.
-
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.Nephrol Dial Transplant. 2009 Jun;24(6):1901-8. doi: 10.1093/ndt/gfn739. Epub 2009 Jan 20. Nephrol Dial Transplant. 2009. PMID: 19155537
-
Serum indoleamine 2,3 dioxygenase and tryptophan and kynurenine ratio using the UPLC-MS/MS method, in patients undergoing peritoneal dialysis, hemodialysis, and kidney transplantation.Ren Fail. 2016 Sep;38(8):1300-9. doi: 10.1080/0886022X.2016.1209389. Epub 2016 Jul 27. Ren Fail. 2016. PMID: 27466137
-
The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression.Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):702-21. doi: 10.1016/j.pnpbp.2010.12.017. Epub 2010 Dec 23. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 21185346 Review.
-
Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.J Biomed Biotechnol. 2011;2011:273907. doi: 10.1155/2011/273907. Epub 2011 Nov 16. J Biomed Biotechnol. 2011. PMID: 22162633 Free PMC article. Review.
Cited by
-
Intersection of the microbiome and immune metabolism in lupus.Immunol Rev. 2024 Aug;325(1):77-89. doi: 10.1111/imr.13360. Epub 2024 Jun 14. Immunol Rev. 2024. PMID: 38873851 Review.
-
From intestinal metabolites to the brain: Investigating the mysteries of Long COVID.Clin Transl Med. 2024 Mar;14(3):e1608. doi: 10.1002/ctm2.1608. Clin Transl Med. 2024. PMID: 38468492 Free PMC article. No abstract available.
-
Dietary tryptophan and genetic susceptibility expand gut microbiota that promote systemic autoimmune activation.bioRxiv [Preprint]. 2024 Jan 19:2024.01.16.575942. doi: 10.1101/2024.01.16.575942. bioRxiv. 2024. PMID: 38293097 Free PMC article. Preprint.
-
A systematic review and meta-analysis of the kynurenine pathway of tryptophan metabolism in rheumatic diseases.Front Immunol. 2023 Oct 23;14:1257159. doi: 10.3389/fimmu.2023.1257159. eCollection 2023. Front Immunol. 2023. PMID: 37936702 Free PMC article.
-
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.RMD Open. 2023 Mar;9(1):e002876. doi: 10.1136/rmdopen-2022-002876. RMD Open. 2023. PMID: 36863752 Free PMC article.
References
-
- Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9(9):664–71. Epub 2001/02/24. . - PubMed
-
- Lood C, Amisten S, Gullstrand B, Jönsen A, Allhorn M, Truedsson L, et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood. 2010;116(11):1951–7. Epub 2010/06/12. doi: blood-2010-03-274605 [pii] 10.1182/blood-2010-03-274605 . - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials